Author

Marjolijn N. Lub–de Hooge

Observed names: Lub-De Hooge, Marjolijn N.; id_orcid 0000-0002-5390-2791, Lub-de Hooge, M. N., Lub-de Hooge, M. N.; id_orcid 0000-0002-5390-2791, Lub-de Hooge, M.N.; id_orcid 0000-0002-5390-2791, Lub-de Hooge, MN, Lub-de Hooge, Marjolijn N.; id_orcid 0000-0002-5390-2791, M N Lub-de Hooge, M. N. Lub-De Hooge, M. N. Lub-de Hooge, M.N. Lub-De Hooge, M.N. Lub-de Hooge, MN Lub-de Hooge, MN Lub‐de Hooge, Marjolijn Lub – de Hooge, Marjolijn Lub-de Hooge, Marjolijn N Lub - de Hooge, Marjolijn N Lub-de Hooge, Marjolijn N. Lub- de Hooge, Marjolijn N. Lub-De Hooge, Marjolijn N. Lub-de Hooge

Institutions: University Medical Center Groningen, University of Groningen

Observed institutions: University Medical Center Groningen, University of Groningen, Genentech, Society of Nuclear Medicine and Molecular Imaging, Ghent University Hospital, University Medical Center Utrecht, Ghent University, The Christie Hospital, Erasmus MC Cancer Institute, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Twente

ORCID: 0000-0002-5390-2791

Observed ORCID: 0000-0002-5390-2791

OpenAlex ID: A5112284530

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

2010 · E C Dijkers, T H Oude Munnink, et al. · Clinical Pharmacology & Therapeutics · 805

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

2018 · Frederike Bensch, Elly L. van der Veen, et al. · Nature Medicine · 732

Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging

2009 · Eli C.F. Dijkers, Jos G.W. Kosterink, et al. · Journal of Nuclear Medicine · 334

Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications

2007 · Guus A.M.S. van Dongen, Gerard W.M. Visser, et al. · The Oncologist · 330

In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft

2007 · W. B. Nagengast, E. G. de Vries, et al. · Journal of Nuclear Medicine · 313

Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

2006 · Patrick J. Perik, Marjolijn N. Lub-De Hooge, et al. · Journal of Clinical Oncology · 310

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

2019 · Frans V. Suurs, Marjolijn N. Lub-de Hooge, et al. · Pharmacology & Therapeutics · 292

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

2016 · Laetitia E. Lamberts, Maximillian Koch, et al. · Clinical Cancer Research · 285

Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis

2006 · Bouke P.C. Hazenberg, Martin H. van Rijswijk, et al. · The American Journal of Medicine · 178

89 Zr-Bevacizumab PET Imaging in Primary Breast Cancer

2013 · Sietske B.M. Gaykema, Adrienne H. Brouwers, et al. · Journal of Nuclear Medicine · 167

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity

2007 · M.A. de Korte, E.G.E. de Vries, et al. · European Journal of Cancer · 160

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

2018 · Frederike Bensch, A. H. Brouwers, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 149

Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

2022 · Laura Kist de Ruijter, Pim P. van de Donk, et al. · Nature Medicine · 137

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

2014 · Sietske B.M. Gaykema, Carolien P. Schröder, et al. · Clinical Cancer Research · 121

Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

2013 · Marlous Arjaans, Thijs H. Oude Munnink, et al. · Cancer Research · 121

VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment

2010 · Wouter B. Nagengast, Marjolijn N. Lub-de Hooge, et al. · Cancer Research · 114

89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment

2014 · Sjoukje F. Oosting, Adrienne H. Brouwers, et al. · Journal of Nuclear Medicine · 113

89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922

2010 · Wouter B. Nagengast, Maarten A. de Korte, et al. · Journal of Nuclear Medicine · 113

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

2020 · Pim P van de Donk, Laura Kist de Ruijter, et al. · Theranostics · 106

Antibody Positron Emission Tomography Imaging in Anticancer Drug Development

2015 · Laetitia E. Lamberts, Simon P. Williams, et al. · Journal of Clinical Oncology · 106

Theranostics Using Antibodies and Antibody-Related Therapeutics

2017 · Kirsten L. Moek, Danique Giesen, et al. · Journal of Nuclear Medicine · 104

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

2015 · Laetitia E. Lamberts, Catharina W. Menke-van der Houven van Oordt, et al. · Clinical Cancer Research · 101

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

2021 · I.C. Kok, J.S. Hooiveld, et al. · Annals of Oncology · 99

89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft

2009 · Thijs H. Oude Munnink, Maarten A. de Korte, et al. · European Journal of Cancer · 98

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review

2023 · T. Y. J. Appeldoorn, T. H. Oude Munnink, et al. · Clinical Pharmacokinetics · 80

Works count: 249

Citation count: 7,729

H-index: 44

I10-index: 85